Ryan Shields, PharmD
The antibiotic pipeline is opening up after decades of decline. Between 2013 and 2023, 13 new antibiotics were approved, many of them beta-lactams, including imipenem-relebactam (IPR; Recarbrio, Merck), cefiderocol (Fetroja, Shionogi) and sulbactam-durlobactam (SUL-DUR; Xacduro, Innoviva). So how do pharmacies decide which of these novel agents to put on the formulary? That was the focus of a session at IDWeek 2023, held in Boston.
Carbapenem-resistant